Shrinking lung syndrome
Rare SLE respiratory complication · Rheumatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A rare pulmonary complication of SLE characterised by unexplained dyspnoea, pleuritic pain and a restrictive defect with small lung volumes but no parenchymal disease, thought to reflect diaphragmatic dysfunction. Diagnosis is one of exclusion once ILD, PE and infection are ruled out.
Red flags
- Rapidly progressive breathlessness (reconsider PE/ILD)
- Hypoxaemia at rest
- Orthopnoea suggesting significant diaphragm weakness
- Signs of pulmonary hypertension
- Fever suggesting infection
Assessment
Differential diagnosis
- Lupus interstitial lung disease
- Pulmonary embolism
- Pleural effusion / serositis
- Diaphragmatic palsy (other cause)
- Pulmonary hypertension
- Infective pneumonia
Investigations
- Chest radiograph (small lung volumes, raised hemidiaphragms, basal atelectasis)
- Pulmonary function tests (restrictive pattern, reduced lung volumes, preserved/normal transfer coefficient)
- High-resolution CT chest (absence of significant parenchymal disease)
- Diaphragmatic ultrasound / sniff test for diaphragm function
- CTPA to exclude pulmonary embolism
- SLE serology (ANA, anti-dsDNA, complement)
Management
- Confirm restrictive physiology with small volumes and no parenchymal cause on HRCT
- Exclude pulmonary embolism, infection and significant effusion
- Assess diaphragmatic function
- Optimise SLE disease control
- Start corticosteroid as first-line therapy
- Add a steroid-sparing immunosuppressant if inadequate response or to allow steroid taper
- Consider beta-agonist / theophylline and physiotherapy for diaphragmatic support in selected cases
- Monitor symptoms and serial lung function
Drugs & doses
Prednisolone — 0.5-1 mg/kg/day PO with gradual taper
Azathioprine — 1.5-2.5 mg/kg/day PO (check TPMT first)
Mycophenolate mofetil — 1 g PO BD if azathioprine unsuitable
Rituximab — 1 g IV days 1 and 15 for refractory disease
Hydroxychloroquine — 200-400 mg PO OD (max 5 mg/kg/day) for background lupus control
Disposition
Outpatient rheumatology/respiratory management with steroids; admit only for significant hypoxaemia or diagnostic uncertainty.
Complications & pitfalls
- Chronic dyspnoea and reduced exercise tolerance
- Respiratory muscle deconditioning
- Recurrent atelectasis
- Steroid-related adverse effects
- Overlap with other lupus lung disease
Exam pearls
- Think of it when an SLE patient has dyspnoea with a restrictive defect but a clear CT parenchyma
- Preserved transfer coefficient (KCO) with reduced volumes points away from ILD
- Generally responds well to corticosteroids
- Diaphragmatic ultrasound is a useful non-invasive confirmatory test
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.